Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899977 · ClinicalTrials.gov registry record · Phase 1
TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
A Phase 1 study, sponsored by Targacept.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00899977 is a Phase 1 study that was terminated before completion, run by Targacept. The registered enrollment target is 1 participants.
The verdict
NCT00899977, a Phase 1 study, was terminated before completion, sponsored by Targacept.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP \> 140 mmHg and a DBP \> 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.
Interventions
- DRUG Placebo
- DRUG TC-5214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899977
The ClinicalTrials.gov registry entry for NCT00899977 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00899977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899977 about?
NCT00899977 is a clinical study titled "TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension". A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP \> 140 mmHg and a DBP \> 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.
What is the current status of trial NCT00899977?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00899977?
The interventions under investigation include: Placebo (DRUG), TC-5214 (DRUG).
Who is sponsoring clinical trial NCT00899977?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.